Retatrutide 10mg lyophilised research peptide, third-party tested

Retatrutide

10mg / Vial
£50.00
£50.00
Skip to product information
Retatrutide 10mg lyophilised research peptide, third-party tested
  • Retatrutide 10mg lyophilised research peptide, third-party tested
  • Retatrutide 10mg lyophilised research peptide, third-party tested
Retatrutide
Best Seller

Retatrutide

£50.00
£50.00
Size
Type
For Research Purposes Only — Not For Human Use This product is intended solely for laboratory and in-vitro research. Not for human consumption, medical use, or self-administration.
Third-party tested
1–2 day tracked dispatch
Discreet packaging
99%+ purity guaranteed
For Research Use OnlyThis compound is strictly for laboratory and in-vitro research. Not for human consumption or medical use.
Reconstitution
Pen format? Pens are supplied pre-mixed and ready for research use — no reconstitution required. The steps below apply to lyophilized vials only.
  1. Swab both vial stoppers with alcohol and allow to dry.
  2. Draw the required volume of bacteriostatic water with a sterile syringe.
  3. Add the water slowly down the inside wall of the vial — never directly onto the powder.
  4. Swirl gently until fully dissolved. Never shake.
  5. Confirm the solution is clear and particle-free.
  6. Label with date and concentration, then refrigerate at 2–8 °C.
Full guide & dose calculator
Storage & Handling
  • Lyophilized vials: refrigerate sealed at 2–8 °C away from light; freeze at −20 °C for storage beyond 6 months.
  • After reconstitution: refrigerate at 2–8 °C; typically stable 4–8 weeks with bacteriostatic water. Do not freeze once mixed.
  • Pre-mixed pens: arrive ready to use — refrigerate at 2–8 °C with the cap on and never freeze.
  • General: avoid direct sunlight, heat and repeated temperature swings; minimise agitation.
Quality & Shipping FAQ
  • Is this compound tested? Yes — every batch is third-party tested by accredited labs (HPLC & mass spectrometry) at 99%+ verified purity.
  • How is it supplied? As lyophilized powder in a sealed sterile vial (or pre-mixed pen where offered), with research-use labelling.
  • How fast is dispatch? 1–2 working day dispatch, 2–3 days UK delivery, in plain discreet packaging.
  • What is it for? Strictly laboratory and in-vitro research — not for human or veterinary consumption, medical use or self-administration.
View the peer-reviewed research
Packaging update Our branded boxes are temporarily out of stock. Until new stock lands, orders ship in plain, discreet packaging — the same product inside, sealed and dispatched with the same care. Thank you for your patience.

Retatrutide

Retatrutide is a synthetic peptide studied in metabolic research as a triple agonist of the GIP, GLP-1 and glucagon receptors.

About the compound

Retatrutide is investigated in laboratory and clinical research for its simultaneous interaction with three receptors involved in metabolic signalling: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Its multi-receptor activity makes it a notable reference compound in metabolic research.

Specifications

  • Purity: 99%+ (third-party verified)
  • Independently tested before dispatch
  • Presented as lyophilised (freeze-dried) powder
  • Supplied for in-vitro laboratory research only

FAQ

Is it tested? Yes — every batch is independently tested to 99%+ purity before dispatch.
What form does it arrive in? Lyophilised powder.
What is this sold for? Laboratory and research use only. Not for human or animal consumption.

⚖ For Laboratory Research Use Only — Not for Human Consumption.
Peer-Reviewed Evidence

Research & Studies

Independent published research on Retatrutide

Retatrutide Metabolic Research Human Phase 2

Retatrutide: Triple GLP-1/GIP/Glucagon Receptor Agonism and 24.2% Weight Loss

New England Journal of Medicine · Jastreboff et al., 2023

Retatrutide is a unimolecular triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 human research demonstrated mean weight reductions of up to 24.2% at 48 weeks — exceeding all previously published weight-loss interventions short of bariatric surgery. Secondary cardiometabolic endpoints showed reductions in waist circumference (up to 13.9 cm), systolic blood pressure, and triglycerides, alongside HbA1c reductions of up to 2.02 percentage points in the diabetic subgroup.

Triple Agonist 24.2% Weight Loss Cardiometabolic
Retatrutide Metabolic Research Human Phase 2

Triple–Hormone-Receptor Agonist Retatrutide for Obesity

New England Journal of Medicine · Jastreboff et al., 2023

A 48-week randomised, double-blind, placebo-controlled phase 2 trial of retatrutide, an agonist of the GIP, GLP-1 and glucagon receptors, in adults with obesity. The highest dose (12 mg once weekly) produced a mean body-weight reduction of 24.2%, with dose-dependent improvements in blood pressure, HbA1c and lipid parameters. These reductions exceeded those previously reported for single- and dual-receptor agonists at the time of publication.

Triple Agonist Body Weight Phase 2 RCT
View the full research library →

You may also like